Suchergebnisse - "Venkatakrishnan, Karthik"

PubPharm (354)

61

Model-informed approach for risk management of bleeding toxicities for bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1

enthalten in: Cancer chemotherapy and pharmacology | 2022

von Vugmeyster, Y. | Grisic, A. | Wilkins, J. | +5

62

Population pharmacokinetic/pharmacodynamic joint modeling of ixazomib efficacy and safety using data from the pivotal phase III TOURMALINE-MM1 study in multiple myeloma patients

enthalten in: CPT: pharmacometrics & systems pharmacology | 2022

von Srimani, J. | Diderichsen, P. | Hanley, M. | +3

63

Diversity and Inclusion in Drug Development : Rethinking Intrinsic and Extrinsic Factors with Patient Centricity

enthalten in: Clinical pharmacology and therapeutics | 2022

von Venkatakrishnan, K. | Benincosa, L.

64

A method for enhancing the pharmacokinetics or increasing the plasma concentration of methyl 3-((methylsulfonyl)amino)-2-(((4-phenylcyclohexyl)oxy)methyl)piperidine-1-carboxylate or a salt thereof with an inhibitor of cytochrome P450

enthalten in: Europäisches Patentamt | 2022

von FAESSEL HELENE | LU HONG | VENKATAKRISHNAN KARTHIK | +3

65

Phase 1 study to evaluate the effects of rifampin on pharmacokinetics of pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors

enthalten in: Investigational new drugs | 2022

von Zhou, X. | Vaishampayan, U. | Mahalingam, D. | +7

66

Phase 1 study to evaluate the effects of rifampin on pharmacokinetics of pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors

enthalten in: Investigational new drugs | 2022

von Zhou, X. | Vaishampayan, U. | Mahalingam, D. | +7

67

Phase 1 study to evaluate the effects of rifampin on pharmacokinetics of pevonedistat, a NEDD8-activating enzyme inhibitor in patients with advanced solid tumors

enthalten in: Investigational new drugs | 2022

von Zhou, X. | Vaishampayan, U. | Mahalingam, D. | +7

68

Quantitative Clinical Pharmacology of CAR T-Cell Therapy

enthalten in: Clinical pharmacology and therapeutics | 2022

von Holstein, S. | Venkatakrishnan, K. | van der Graaf, P.

CommentOn: Clin Pharmacol Ther. 2022 Jul;112(1):81-89. - PMID 35156195

69

Exposure-response analyses for the MET inhibitor tepotinib including patients in the pivotal VISION trial : support for dosage recommendations

enthalten in: Cancer chemotherapy and pharmacology | 2022

von Xiong, W. | Hietala, S. | Nyberg, J. | +8

70

- BORON-CONTAINING PROTEASOME INHIBITORS FOR USE AFTER PRIMARY CANCER THERAPY

enthalten in: Europäisches Patentamt | 2022

von HUI AI MIN | LABOTKA RICHARD | GUPTA NEERAJ | +2